CN105377890A - Vegf拮抗剂治疗早产儿视网膜病变的用途 - Google Patents

Vegf拮抗剂治疗早产儿视网膜病变的用途 Download PDF

Info

Publication number
CN105377890A
CN105377890A CN201480039605.XA CN201480039605A CN105377890A CN 105377890 A CN105377890 A CN 105377890A CN 201480039605 A CN201480039605 A CN 201480039605A CN 105377890 A CN105377890 A CN 105377890A
Authority
CN
China
Prior art keywords
dose
vegf antagonist
administered
vegf
ranibizumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480039605.XA
Other languages
English (en)
Chinese (zh)
Inventor
G·布莱恩
S·阿克赛诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN105377890A publication Critical patent/CN105377890A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A61F9/00823—Laser features or special beam parameters therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
CN201480039605.XA 2013-07-11 2014-07-10 Vegf拮抗剂治疗早产儿视网膜病变的用途 Pending CN105377890A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845073P 2013-07-11 2013-07-11
US61/845,073 2013-07-11
PCT/IB2014/063003 WO2015004626A2 (en) 2013-07-11 2014-07-10 Use of a vegf antagonist in treating retinopathy of prematurity

Publications (1)

Publication Number Publication Date
CN105377890A true CN105377890A (zh) 2016-03-02

Family

ID=51211284

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480039605.XA Pending CN105377890A (zh) 2013-07-11 2014-07-10 Vegf拮抗剂治疗早产儿视网膜病变的用途

Country Status (14)

Country Link
US (1) US20160159893A1 (cg-RX-API-DMAC7.html)
EP (1) EP3019527A2 (cg-RX-API-DMAC7.html)
JP (1) JP2016523956A (cg-RX-API-DMAC7.html)
KR (1) KR20160030504A (cg-RX-API-DMAC7.html)
CN (1) CN105377890A (cg-RX-API-DMAC7.html)
AR (1) AR096893A1 (cg-RX-API-DMAC7.html)
AU (3) AU2014288847A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016000282A2 (cg-RX-API-DMAC7.html)
CA (1) CA2917813A1 (cg-RX-API-DMAC7.html)
HK (1) HK1221231A1 (cg-RX-API-DMAC7.html)
MX (1) MX2016000385A (cg-RX-API-DMAC7.html)
RU (1) RU2676303C2 (cg-RX-API-DMAC7.html)
TW (1) TW201536317A (cg-RX-API-DMAC7.html)
WO (1) WO2015004626A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
BRPI1006897A2 (pt) 2009-07-06 2015-09-08 Akebia Therapeutics Inc compostos, composições e métodos de prevenção da metástase de células cancerosas.
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
US10973867B2 (en) 2015-12-30 2021-04-13 Marshall University Research Corporation Compositions and methods for treating retinopathy
SG10201912556VA (en) 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
JP7564824B2 (ja) 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ, インコーポレイテッド シュレム管を標的とするTie-2活性化物質
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020972A2 (en) * 2003-08-27 2005-03-10 (Osi) Eyetech, Inc. Combination therapy for the treatment of ocular neovascular disorders
WO2013057183A1 (en) * 2011-10-20 2013-04-25 Avienne Pharmaceuticals Gmbh Compositions for controlling vascularization in ophthalmological and dermatological diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4596916B2 (ja) * 2002-09-05 2010-12-15 メディミューン,エルエルシー Cd2拮抗薬を投与することによりt細胞悪性腫瘍を予防または治療する方法
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
JP5838021B2 (ja) * 2005-04-15 2015-12-24 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディとその使用
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
AU2008325142A1 (en) * 2007-11-07 2009-05-14 Anthrogenesis Corporation Use of umbilical cord blood in the treatment of premature birth complications
CN102215875B (zh) * 2008-10-16 2014-08-06 凯瑟琳·科根·法瑞纳斯 持续药物递送系统
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
JP2012525415A (ja) * 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制vegf-a受體交互作用的經修飾結合性蛋白質
RU2469734C2 (ru) * 2010-09-02 2012-12-20 Григорий Владимирович Пантелеев Лечебное средство для лечения расстройств аккомодаций "stiak"
BR112015003658B1 (pt) * 2012-08-21 2022-09-27 Opko Pharmaceuticals, Llc Formulação oftálmica, uso da dita formulação no tratamento de doença oftálmica do segmento posterior, formulação de lipossomas e suspensão oftálmica lipossomal

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020972A2 (en) * 2003-08-27 2005-03-10 (Osi) Eyetech, Inc. Combination therapy for the treatment of ocular neovascular disorders
WO2013057183A1 (en) * 2011-10-20 2013-04-25 Avienne Pharmaceuticals Gmbh Compositions for controlling vascularization in ophthalmological and dermatological diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHUN-JU LIN等: "Effects of ranibizumab on very low birth weight infants with stage 3 retinopathy of prematurity: A preliminary report", 《TAIWAN JOURNAL OF OPHTHALMOLOGY》 *

Also Published As

Publication number Publication date
WO2015004626A2 (en) 2015-01-15
AR096893A1 (es) 2016-02-03
CA2917813A1 (en) 2015-01-15
BR112016000282A2 (pt) 2017-12-12
TW201536317A (zh) 2015-10-01
AU2019206000A1 (en) 2019-08-01
JP2016523956A (ja) 2016-08-12
WO2015004626A3 (en) 2015-05-28
KR20160030504A (ko) 2016-03-18
US20160159893A1 (en) 2016-06-09
RU2676303C2 (ru) 2018-12-27
RU2016104398A (ru) 2017-08-16
EP3019527A2 (en) 2016-05-18
MX2016000385A (es) 2016-04-29
HK1221231A1 (zh) 2017-05-26
AU2014288847A1 (en) 2016-01-28
AU2017204326A1 (en) 2017-07-13
RU2016104398A3 (cg-RX-API-DMAC7.html) 2018-05-31

Similar Documents

Publication Publication Date Title
AU2017203923B2 (en) Use of a VEGF antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
AU2019206000A1 (en) Use of a VEGF antagonist in treating retinopathy of prematurity
JP7273204B2 (ja) 眼科疾患の処置
JP2016522249A (ja) 脈絡膜血管新生の治療におけるvegfアンタゴニストの使用
BR112020010659A2 (pt) uso de um antagonista do vegf para tratar disfunções oftalmológicas angiogênicas
WO2014033184A1 (en) Use of a vegf antagonist in treating ocular vascular proliferative diseases
Yang et al. A randomized controlled trial of conbercept pretreatment before vitrectomy in proliferative diabetic retinopathy
JP2017536414A (ja) 血管性眼疾患を処置するための方法および製剤
EP2377553A1 (en) Use of IL-1 antibodies for treating ophthalmic disorders
US20160130321A1 (en) Use of a vegf antagonist in treating macular edema
JP2016522248A (ja) ポリープ状脈絡膜血管症の治療
CN113645994A (zh) 使用色素上皮衍生因子(pedf)治疗疾病的方法
KR20220062279A (ko) 안질환의 치료 방법
TW201904610A (zh) 用於治療新生血管型青光眼之非抗體vegf拮抗劑
KR20230061502A (ko) 황반 변성 또는 맥락막 혈관신생 치료에 사용하기 위한 색소 상피-유래 인자(pedf)
Sundlisæter et al. Antiangiogenic treatment of ocular diseases
Jacob et al. STUDY ON CHANGE IN VISUAL ACUITY FOLLOWING INTRAVITREAL INJECTION OF ANTI VEGF (BEVACIZUMAB) IN PATIENTS WITH DIABETIC MACULAR EDEMA

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160302